伴侶動物藥品市場規模、佔有率及成長分析（依產品類型、動物種類、給藥途徑、通路及地區分類）－2026-2033年產業預測

全球伴侶動物藥品市場規模預計在 2024 年達到 172 億美元，從 2025 年的 186.1 億美元成長到 2033 年的 349.7 億美元，在預測期（2026-2033 年）內複合年成長率為 8.2%。

全球伴侶動物藥品市場正經歷強勁成長，這主要得益於寵物飼養率的上升以及人們日益增強的動物福利意識推動了寵物健康支出的增加。抗感染劑、疫苗、疼痛管理方案和皮膚病產品的需求激增，尤其是針對犬貓這種主要伴侶動物。獸醫診斷和藥物傳輸技術的進步，以及個人化寵物醫療的興起，正在推動市場創新。關節炎和肥胖等慢性疾病發生率的上升，也促使人們對持續治療方案的需求日益成長。寵物人性化的趨勢，尤其是在北美和歐洲，以及獸醫遠端照護和線上藥局的興起，都提高了寵物獲得治療的便利性。同時，亞太和拉丁美洲地區由於經濟發展和獸醫基礎設施的改善，也展現出巨大的成長潛力。

全球伴侶動物藥品市場促進因素

全球伴侶動物藥品市場的主要促進因素之一是寵物飼養的日益普及以及人們對動物健康和福利意識的不斷提高。隨著越來越多的家庭飼養寵物，對先進獸醫服務的需求也不斷成長，包括預防性藥物、慢性病治療和綜合健康管理方案。此外，寵物飼主越來越意識到定期帶寵物就診和藥物干預的重要性，從而推動了對創新藥物研發和治療方法的投資。獸醫學的進步以及寵物作為家庭成員地位的日益提升，進一步強化了這一趨勢。

限制全球伴侶動物藥品市場的因素

全球伴侶動物藥品市場的主要阻礙因素之一是動物用藥品監管審查日益嚴格，核准流程也更加嚴苛。這種複雜性導致研發週期延長、生產成本上升，阻礙創新和市場准入，尤其對中小企業而言更是如此。此外，嚴格的合規要求限制了新產品的供應，影響了市場的整體成長潛力。而且，產品召回和安全問題會削弱消費者信心，進一步抑制該產業的需求和投資。這些監管挑戰對希望擴大市場佔有率的相關人員構成了持續的障礙。

全球伴侶動物醫藥市場趨勢

全球伴侶動物藥品市場正呈現向高階治療藥物發展的顯著趨勢，這主要得益於寵物日益擬人化的趨勢。寵物飼主越來越希望獲得與人類同等水平的醫療保健解決方案，從而推動了針對文明病、心理健康和疼痛管理的治療方法需求。這種轉變促進了處方藥、長效注射和抗焦慮藥物的成長，尤其是在寵物擁有率高、動物福利意識普遍增強的都市區。隨著消費者越來越將寵物視為家庭成員，市場亟需進一步的創新和產品開發，以滿足這些不斷變化的需求。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

全球伴侶動物藥品市場規模（依產品及複合年成長率分類）（2026-2033 年）

• 製藥
  • 抗寄生蟲藥物
  • 抗發炎藥
  • 抗感染劑
  • 皮質類固醇
  • 鎮靜劑
  • 循環系統藥物
  • 消化器官系統藥物
• 疫苗
  • 減毒活病毒疫苗（MLV）
  • 去活化疫苗
  • 重組疫苗
• 藥用飼料添加劑
  • 抗生素
  • 維他命
  • 胺基酸
  • 酵素
  • 抗氧化劑
  • 益生元和益生菌
  • 礦物
  • 碳水化合物
  • 丙二醇

全球伴侶動物藥品市場規模（以動物類型分類）及複合年成長率（2026-2033 年）

• 狗
• 貓
• 馬
• 其他動物物種

全球伴侶動物藥品市場規模（依給藥途徑及複合年成長率分類）（2026-2033 年）

• 口服
• 注射
• 外用
• 其他給藥途徑

全球伴侶動物藥品市場規模（依通路分類）及複合年成長率（2026-2033 年）

• 獸醫院藥房
• 電子商務
• 零售藥房

全球伴侶動物藥品市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Zoetis Inc.（United States）
• Boehringer Ingelheim International GmbH（Germany）
• Merck & Co., Inc.（United States）
• Elanco Animal Health Incorporated（United States）
• IDEXX Laboratories, Inc.（United States）
• Virbac SA（France）
• Ceva Sante Animale SA（France）
• Dechra Pharmaceuticals PLC（United Kingdom）
• Vetoquinol SA（France）
• Phibro Animal Health Corporation（United States）
• Bayer AG（Germany）
• Norbrook Laboratories（United Kingdom）
• Krka, dd, Novo mesto（Slovenia）
• Intas Pharmaceuticals（India）
• Hester Biosciences Ltd.（India）
• Zydus Animal Health（India）
• Abbott Laboratories（United States）
• IDT Biologika（Germany）
• Bimeda（Ireland）
• Neogen Corporation（United States）

結論與建議

Global Companion Animal Pharmaceuticals Market size was valued at USD 17.2 Billion in 2024 and is poised to grow from USD 18.61 Billion in 2025 to USD 34.97 Billion by 2033, growing at a CAGR of 8.2% during the forecast period (2026-2033).

The global companion animal pharmaceuticals market is experiencing robust growth, propelled by rising pet adoption and increased expenditure on pet health fueled by heightened awareness of animal welfare. Demand for anti-infectives, anti-parasitics, vaccines, pain management solutions, and dermatology products is surging, particularly for dogs and cats, the predominant companion species. Advancements in veterinary diagnostics and drug delivery technologies, alongside the rise of personalized medicine for pets, are driving market innovation. The growing incidence of chronic conditions, such as arthritis and obesity in companion animals, increases the need for ongoing therapeutic options. Trends relating to pet humanization, particularly in North America and Europe, along with the rise of veterinary telemedicine and e-pharmacies, enhance treatment accessibility, while Asia-Pacific and Latin America exhibit significant growth potential due to economic development and improved veterinary infrastructure.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Companion Animal Pharmaceuticals market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Companion Animal Pharmaceuticals Market Segments Analysis

Global Companion Animal Pharmaceuticals Market is segmented by Product, Animal Type, Route of Administration, Distribution Channel and region. Based on Product, the market is segmented into Drugs, Vaccines and Medicated feed additives. Based on Animal Type, the market is segmented into Dogs, Cats, Horses and Other animal types. Based on Route of Administration, the market is segmented into Oral, Injectable, Topical and Other routes of administration. Based on Distribution Channel, the market is segmented into Veterinary hospital pharmacies, E-commerce and Retail pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Companion Animal Pharmaceuticals Market

One of the key market drivers for the global companion animal pharmaceuticals market is the increasing prevalence of pet ownership and the growing awareness of animal health and welfare. As more households adopt pets, there is a rising demand for advanced veterinary care, including preventive medications, treatments for chronic diseases, and overall health management solutions. Additionally, pet owners are becoming more educated about the importance of regular veterinary visits and pharmaceutical interventions, driving investment in innovative drug development and therapeutic treatments. This trend is further supported by advancements in veterinary medicine and the humanization of pets, emphasizing their role as family members.

Restraints in the Global Companion Animal Pharmaceuticals Market

One significant restraint in the Global Companion Animal Pharmaceuticals Market is the increasing regulatory scrutiny and stringent approval processes for veterinary drugs. This complexity can lead to longer development timelines and higher costs for manufacturers, discouraging innovation and market entry, particularly for smaller firms. Additionally, the rigorous compliance requirements can limit the availability of new products, impacting the overall growth potential of the market. Furthermore, issues related to product recalls and safety concerns can undermine consumer trust, further dampening demand and investment in this sector. These regulatory challenges present ongoing obstacles for stakeholders aiming to expand their presence in the market.

Market Trends of the Global Companion Animal Pharmaceuticals Market

The Global Companion Animal Pharmaceuticals market is experiencing a notable trend towards premium therapeutics, fueled by the increasing humanization of pets. Pet owners are seeking healthcare solutions that mirror those available for humans, leading to a rising demand for therapies addressing lifestyle diseases, mental wellness, and pain management. This shift is propelling the growth of prescription therapeutics, long-acting injectables, and anti-anxiety treatments, particularly in urban areas where pet ownership and sentiment towards animal welfare are heightened. As consumers increasingly view their pets as family members, the market is poised for further innovations and product developments tailored to meet these evolving needs.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Companion Animal Pharmaceuticals Market Size by Product & CAGR (2026-2033)

• Market Overview
• Drugs
  • Antiparasitic
  • Anti-inflammatory
  • Anti-infectives
  • Corticosteroids
  • Tranquilizers
  • Cardiovascular drugs
  • Gastrointestinal drugs
• Vaccines
  • Modified live vaccines (MLV)
  • Killed inactivated vaccines
  • Recombinant vaccines
• Medicated feed additives
  • Antibiotics
  • Vitamins
  • Amino acids
  • Enzymes
  • Antioxidants
  • Prebiotics and probiotics
  • Minerals
  • Carbohydrates
  • Propanediol

Global Companion Animal Pharmaceuticals Market Size by Animal Type & CAGR (2026-2033)

• Market Overview
• Dogs
• Cats
• Horses
• Other animal types

Global Companion Animal Pharmaceuticals Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Injectable
• Topical
• Other routes of administration

Global Companion Animal Pharmaceuticals Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Veterinary hospital pharmacies
• E-commerce
• Retail pharmacies

Global Companion Animal Pharmaceuticals Market Size & CAGR (2026-2033)

• North America (Product, Animal Type, Route of Administration, Distribution Channel)
  • US
  • Canada
• Europe (Product, Animal Type, Route of Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Animal Type, Route of Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Animal Type, Route of Administration, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Animal Type, Route of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Zoetis Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Elanco Animal Health Incorporated (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IDEXX Laboratories, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Virbac S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ceva Sante Animale S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dechra Pharmaceuticals PLC (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vetoquinol S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Phibro Animal Health Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Norbrook Laboratories (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Krka, d. d., Novo mesto (Slovenia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intas Pharmaceuticals (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hester Biosciences Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Animal Health (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IDT Biologika (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bimeda (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neogen Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations